Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
J Vector Borne Dis ; 61(1): 81-89, 2024 Jan 01.
Article in English | MEDLINE | ID: mdl-38648409

ABSTRACT

BACKGROUND OBJECTIVES: Malaria due to Plasmodium falciparum (Pf) remains a major public threat in India. Artemisinin-based combination therapy (ACT) has been the country's first-line drug for uncomplicated Pf malaria. In 2013-2014, Artesunate plus sulfadoxine (AS+SP) was replaced by Artemether Lumefantrine (AL) as the first- line antimalarial in North East (NE) states of the country which are endemic for Pf malaria. Regular monitoring of antimalarial drugs is of utmost importance to achieve the goal of elimination. This study aimed to assess the efficacy and safety of ACT for treating uncomplicated Pf malaria in the NE states of India. METHODS: A prospective study of 28-day follow-up was conducted to monitor the efficacy and safety of AL from 2018-2019 in four districts, Udalgiri, Meghalaya, Lawngtlai, and Dhalai of NE, India. The clinical and parasitological response and the polymorphism analysis of the Pfdhps, P/dhfr, and Pfkelch 13 gene were evaluated. RESULTS: A total of 234 patients were enrolled in the study out of 216 patients who completed the follow-up to 28 days. One-hundred percent adequate clinical and parasitological responses (ACPR) were observed with polymerase chain reaction (PCR) correction. The genotype results suggest no recrudescence in the treatment-failure patients. The classical single nucleotide polymorphisms (SNP) in the Pfdhfr gene was S108N (94.9%), followed by C59R (91.5%), whereas, in the Pfdhps gene, the common SNP was A437G (79.6%), followed by S3436A. No associated or validated mutations were found in the propeller region of the PfKelch13 gene. INTERPRETATION CONCLUSION: AL was efficacious and safe in uncomplicated P. falciparum malaria in North East India. In contrast, mutations in the genes responsible for sulfadoxine and pyrimethamine resistance have been fixed in northeast India's population.


Subject(s)
Antimalarials , Artemisinins , Drug Therapy, Combination , Malaria, Falciparum , Plasmodium falciparum , Malaria, Falciparum/drug therapy , Malaria, Falciparum/parasitology , India , Humans , Artemisinins/therapeutic use , Artemisinins/adverse effects , Antimalarials/therapeutic use , Antimalarials/administration & dosage , Antimalarials/adverse effects , Female , Male , Plasmodium falciparum/genetics , Plasmodium falciparum/drug effects , Prospective Studies , Adult , Young Adult , Adolescent , Middle Aged , Treatment Outcome , Child , Child, Preschool , Artemether, Lumefantrine Drug Combination/therapeutic use , Sulfadoxine/therapeutic use , Drug Combinations
2.
J Environ Manage ; 326(Pt A): 116674, 2023 Jan 15.
Article in English | MEDLINE | ID: mdl-36410302

ABSTRACT

Ferrochrome slag (FCS) is a by-product of ferrochrome industries and is produced during the extraction of ferrochrome from chromite ore. The chemical composition of FCS comprises of 27-33% SiO2, 15-25% Al2O3, 20-35% MgO, and 10-15% iron-chromium compounds. The high chromium content of FCS and the possibility of its leaching into the environment categorize FCS as hazardous waste material. For each ton of ferrochrome production, nearly 1.2-1.5 tons of FCS is generated, which becomes a significant challenge for the ferrochrome producers while managing this hazardous waste. Therefore, several research attempts have been made to observe the leaching characteristics of chromium (VI) in FCS, its stabilization, and subsequent potential utilization. The high mechanical properties of FCS have led many researchers worldwide to utilize it as a construction material. This review work has undertaken FCS's physical, chemical, and microstructural characteristics and its following utilization as a fine and coarse aggregate in producing green and sustainable concrete. Different methods of stabilizing chromium (VI), including the physical, chemical, and biological methods, are extensively discussed in this review. This article also accommodated FCS as a precursor material in geopolymer and alkali-activated binders. However, the compressive strength achieved with FCS as a binder in geopolymer is very low, and thus more studies are needed to establish the possibility of strength enhancement. The leaching aspects of geopolymers with FCS also need to be studied extensively for their successive application. Lastly, the conclusions and discussion of this study have keenly addressed the significant challenges to the safe utilization of FCS in construction applications. Also, it deliberates on how the emerging research on FCS, such as refractory, composites, and coating material, can be new avenues for its utilization without any potential threat to the environment.


Subject(s)
Alkalies , Silicon Dioxide , Chromium , Hazardous Substances , Hazardous Waste
3.
Br J Cancer ; 125(4): 547-560, 2021 08.
Article in English | MEDLINE | ID: mdl-34079080

ABSTRACT

BACKGROUND: Overexpression of anti-apoptotic MCL-1 protein in oral squamous cell carcinoma (OSCC) is linked to disease progression, therapy resistance and poor outcome. Despite its characteristic short half-life owing to ubiquitin-proteasome-dependent degradation, oral tumours frequently show elevated MCL-1 protein expression. Hence, we investigated the role of deubiquitinase USP9X in stabilising MCL-1 protein and its contribution to oral tumorigenesis. METHODS: Expression of MCL-1 and USP9X was assessed by immunoblotting and immunohistochemistry in oral cancer cell lines and tissues. The association between MCL-1 and USP9X was confirmed by coimmunoprecipitation and immunofluorescence. Cell death assessment was performed by MTT, flow cytometry and clonogenic assays. RESULTS: Both USP9X and MCL-1 are significantly elevated in oral premalignant lesions and oral tumours versus normal mucosa. USP9X interacts with and deubiquitinates MCL-1, thereby stabilising it. Pharmacological inhibition of USP9X potently induced cell death in OSCC cells in vitro and in vivo. The elevated expression of USP9X and MCL-1 correlated with poor prognosis in OSCC patients. CONCLUSION: We demonstrate the oncogenic role of USP9X in driving early-to-late stages of oral tumorigenesis via stabilisation of MCL-1, suggesting its potential as a prognostic biomarker and therapeutic target in oral cancers.


Subject(s)
Carcinoma, Squamous Cell/pathology , Mouth Neoplasms/pathology , Myeloid Cell Leukemia Sequence 1 Protein/chemistry , Ubiquitin Thiolesterase/metabolism , Up-Regulation , Animals , Carcinoma, Squamous Cell/genetics , Carcinoma, Squamous Cell/metabolism , Cell Line, Tumor , Female , Gene Expression Regulation, Neoplastic , Humans , Mice , Mouth Neoplasms/genetics , Mouth Neoplasms/metabolism , Myeloid Cell Leukemia Sequence 1 Protein/metabolism , Neoplasm Staging , Neoplasm Transplantation , Prognosis , Protein Stability , Survival Analysis , Ubiquitin Thiolesterase/genetics , Ubiquitination
4.
J Stroke Cerebrovasc Dis ; 30(7): 105805, 2021 Jul.
Article in English | MEDLINE | ID: mdl-33892314

ABSTRACT

INTRODUCTION: There is limited literature on coronavirus disease 2019 (COVID -19) complications such as thromboembolism, cardiac complications etc. as possible trigger for stroke. Hence, we aim to evaluate the prevalence and outcomes of COVID-19 related cardiovascular complications and secondary infection and their possibility as potential triggers for the stroke. METHODS: Data from observational studies describing the complications [acute cardiac injury (ACI), cardiac arrhythmias (CA), disseminated intravascular coagulation (DIC), septic shock, secondary infection] and outcomes of COVID-19 hospitalized patients from December 1, 2019 to June 30, 2020, were extracted following PRISMA guidelines. Adverse outcomes defined as intensive care units, oxygen saturation less than 90%, invasive mechanical ventilation, severe disease, and in-hospital mortality. The odds ratio and 95% confidence interval were obtained, and forest plots were created using random-effects models. A short review of these complications as triggers of stroke was conducted. RESULTS: 16 studies with 3480 confirmed COVID-19 patients, prevalence of ACI [38%vs5.9%], CA [26%vs5.3%], DIC [4%vs0.74%], septic shock [18%vs0.36%], and infection [30%vs12.5%] was higher among patients with poor outcomes. In meta-analysis, ACI [aOR:9.93(95%CI:3.95-25.00], CA [7.52(3.29-17.18)], DIC [7.36(1.24-43.73)], septic shock [30.12(7.56-120.10)], and infection [10.41(4.47-24.27)] had higher odds of adverse outcomes. Patients hospitalized with acute ischemic stroke and intracerebral hemorrhage, had complications like pulmonary embolism, venous thromboembolism, DIC, etc. and had poor outcomes CONCLUSION: The complications like acute cardiac injury, cardiac arrhythmias, DIC, septic shock, and secondary infection had poor outcomes. Patients with stroke were having history of these complications. Long term monitoring is required in such patients to prevent stroke and mitigate adverse outcomes.


Subject(s)
Arrhythmias, Cardiac/epidemiology , COVID-19/epidemiology , Disseminated Intravascular Coagulation/epidemiology , Ischemic Stroke/epidemiology , Venous Thromboembolism/epidemiology , Adult , Aged , Arrhythmias, Cardiac/diagnosis , Arrhythmias, Cardiac/mortality , Arrhythmias, Cardiac/therapy , COVID-19/diagnosis , COVID-19/mortality , COVID-19/therapy , Disseminated Intravascular Coagulation/diagnosis , Disseminated Intravascular Coagulation/mortality , Disseminated Intravascular Coagulation/therapy , Female , Hospital Mortality , Hospitalization , Humans , Ischemic Stroke/diagnosis , Ischemic Stroke/mortality , Ischemic Stroke/therapy , Male , Middle Aged , Observational Studies as Topic , Prevalence , Prognosis , Risk Assessment , Risk Factors , Time Factors , Venous Thromboembolism/diagnosis , Venous Thromboembolism/mortality , Venous Thromboembolism/therapy
5.
Blood Cells Mol Dis ; 88: 102464, 2021 05.
Article in English | MEDLINE | ID: mdl-32653327

ABSTRACT

Pure red cell aplasia is a known complication after ABO incompatible stem cell transplant. Due to rarity of disease, no established treatment guidelines are available for PRCA. Daratumumab is a monoclonal antibody against CD38 expressed by plasma cells. In this report we present our experience of successfully managing a patient of post-transplant PRCA with daratumumab. Our patient had failed multiple lines of therapy prior to receiving daratumumab. Response was seen after the 3rd weekly dose of daratumumab.


Subject(s)
ABO Blood-Group System/immunology , Antibodies, Monoclonal/therapeutic use , Antineoplastic Agents, Immunological/therapeutic use , Blood Group Incompatibility/complications , Hematopoietic Stem Cell Transplantation/adverse effects , Red-Cell Aplasia, Pure/drug therapy , ADP-ribosyl Cyclase 1/antagonists & inhibitors , ADP-ribosyl Cyclase 1/immunology , Adolescent , Anemia, Aplastic/immunology , Anemia, Aplastic/therapy , Blood Group Incompatibility/immunology , Female , Humans , Red-Cell Aplasia, Pure/etiology , Red-Cell Aplasia, Pure/immunology , Transplantation, Homologous/adverse effects
SELECTION OF CITATIONS
SEARCH DETAIL
...